LMNL Liminal BioSciences Inc. Stock Quote

LMNL [NASD]

Index	-	P/E	0.26	EPS (ttm)	20.00	Insider Own	67.67%	Shs Outstand	23.59M	Perf Week	-8.77%
Market Cap	147.29M	Forward P/E	-	EPS next Y	-0.72	Insider Trans	0.00%	Shs Float	9.50M	Perf Month	3.24%
Income	-93.10M	PEG	-	EPS next Q	-0.59	Inst Own	6.80%	Short Float	1.88%	Perf Quarter	-10.68%
Sales	2.60M	P/S	56.65	EPS this Y	93.90%	Inst Trans	-37.63%	Short Ratio	0.12	Perf Half Y	-52.78%
Book/sh	1.21	P/B	4.21	EPS next Y	74.30%	ROA	-	Target Price	-	Perf Year	-54.50%
Cash/sh	0.99	P/C	5.17	EPS next 5Y	-	ROE	-	52W Range	3.51 - 31.45	Perf YTD	21.43%
Dividend	-	P/FCF	-	EPS past 5Y	-27.80%	ROI	-149.20%	52W High	-83.78%	Beta	1.85
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	-26.60%	Gross Margin	36.50%	52W Low	45.30%	ATR	0.49
Employees	300	Current Ratio	2.20	Sales Q/Q	-25.00%	Oper. Margin	-	RSI (14)	54.24	Volatility	7.22% 8.78%
Optionable	No	Debt/Eq	2.10	EPS Q/Q	22.70%	Profit Margin	-	Rel Volume	0.26	Prev Close	5.15
Shortable	Yes	LT Debt/Eq	1.89	Earnings	-	Payout	-	Avg Volume	1.44M	Price	5.10
Recom	2.70	SMA20	7.56%	SMA50	13.42%	SMA200	-43.40%	Volume	373,509	Change	-0.97%

Dec-21-20

Initiated

Piper Sandler

Overweight

$22

Jan-21-21 08:30AM	Vivid Capital Management Formally Announces Energy Transition Fund Strategy CNW Group
Jan-12-21 09:00AM	Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center PR Newswire +26.58%
09:00AM	Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center CNW Group
Jan-06-21 09:55AM	Excalibur Data Systems Announces A New Managed Services Offering CNW Group
Dec-15-20 09:20AM	Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras PR Newswire
09:20AM	Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras CNW Group
Dec-11-20 11:11AM	Government of Canada announces funding to support 16 economic development projects in northern Manitoba CNW Group
Dec-01-20 08:00AM	NOTICE TO THE MEDIA - COVID-19 Update (December 1, 2020) - Ministers and Government of Canada officials to hold a news conference on coronavirus disease CNW Group
Nov-13-20 09:20AM	Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference CNW Group -10.68%
Nov-12-20 04:57PM	Liminal BioSciences Reports Third Quarter Financial Results PR Newswire
04:57PM	Liminal BioSciences Reports Third Quarter Financial Results CNW Group
Nov-10-20 06:33PM	Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call PR Newswire
06:33PM	Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call CNW Group
Nov-08-20 07:01PM	Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA PR Newswire
Nov-06-20 09:26AM	Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call PR Newswire
Nov-05-20 04:35AM	Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition PR Newswire
04:35AM	Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition CNW Group
Oct-30-20 08:30AM	Liminal BioSciences Announces Private Placement Financing of USD$30 Million PR Newswire -8.00%
08:30AM	Liminal BioSciences Announces Private Placement Financing of USD$30 Million CNW Group
Oct-07-20 09:30AM	Canada and Nova Scotia invest in a new community centre for Sheet Harbour CNW Group
Sep-21-20 08:16AM	Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen) PR Newswire -7.87%
08:16AM	Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen) CNW Group
Sep-09-20 08:00AM	Liminal BioSciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference PR Newswire +5.89%
Sep-08-20 06:00AM	Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital Plasminogen Deficiency PR Newswire
Sep-01-20 08:36AM	Liminal BioSciences Announces New Appointments to its Board of Directors PR Newswire
08:36AM	Liminal BioSciences Announces New Appointments to its Board of Directors CNW Group
Aug-25-20 08:49AM	theScore Closes $25 Million Bought Deal Financing CNW Group -13.17%
Aug-24-20 01:30PM	Trump Announces Authorization of Blood Plasma Covid Treatment. The Only Hitch: It Might Not Work. Barrons.com
10:03AM	Price Over Earnings Overview: Liminal Biosciences Benzinga
Aug-10-20 05:01PM	Liminal BioSciences reports financial results for Q2-2020 PR Newswire
Aug-06-20 05:01PM	Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference PR Newswire
Jul-22-20 07:55AM	Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange PR Newswire -6.42%
Jul-17-20 08:00AM	Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases PR Newswire
Jul-02-20 11:16AM	Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy CNW Group -26.50%
Jun-30-20 05:31PM	Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors PR Newswire
05:31PM	Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors CNW Group
05:00PM	Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020 PR Newswire
05:00PM	Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020 CNW Group
Jun-11-20 05:00PM	Liminal BioSciences to Present at Raymond James Human Health Innovation Conference CNW Group -8.72%
Jun-09-20 03:53PM	Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM) PR Newswire
03:53PM	Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM) CNW Group
May-28-20 05:30PM	Liminal BioSciences to present at Jefferies Virtual Healthcare Conference CNW Group -9.51%
May-22-20 07:14AM	Investors Who Bought Liminal BioSciences (TSE:LMNL) Shares Five Years Ago Are Now Down 100% Simply Wall St.
May-13-20 05:00PM	Liminal Biosciences Reports Q1 2020 Results PR Newswire +6.02%
Mar-23-20 06:30AM	Liminal BioSciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-22-20 03:23PM	Liminal BioSciences comments on Coronavirus (COVID-19) PR Newswire
03:23PM	Liminal BioSciences comments on Coronavirus (COVID-19) CNW Group
Mar-20-20 05:01PM	Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results PR Newswire +9.60%
05:01PM	Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results CNW Group
05:00PM	Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast PR Newswire
Feb-12-20 07:30AM	Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia PR Newswire
07:30AM	Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia CNW Group
Feb-06-20 07:30AM	Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor Conference CNW Group
Jan-13-20 07:00AM	Liminal BioSciences Outlines Corporate Priorities for 2020 PR Newswire -11.52%
07:00AM	Liminal BioSciences Outlines Corporate Priorities for 2020 CNW Group
Dec-23-19 03:43PM	Liminal BioSciences Comments on Unusual Market Activity CNW Group +81.85%
Nov-28-19 04:40PM	AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019 PR Newswire
04:40PM	AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019 CNW Group
Nov-27-19 07:30AM	Liminal BioSciences to Present at Piper Jaffray Healthcare Conference CNW Group
Nov-25-19 12:03PM	Liminal BioSciences announces closing of divestiture of bioseparations division to KKR CNW Group
Nov-18-19 07:30AM	Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus Supplement PR Newswire +16.15%

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alstrom Syndrome. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience